On January 30, 2023 Hervor Therapeutics reported the company received HV-101 IND clearance for Phase I/II Clinical Trial from NMPA (Press release, Hervor Therapeutics, JAN 30, 2023, View Source [SID1234638949]). HV-101 is an process-optimized, autologous unmodified Tumor-infiltrating lymphocyte (TIL) product fully developed at Hervor. Comparing to conventional TIL product, HV-101 has significant more percentage of stem-progenitor T cells and better functionality.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In the coming phase I/II clinical study, the company will investigate the safety, tolerability, and preliminary Efficacy of HV-101 for patients with recurrent or metastatic solid tumors.